How to buy Corbus Pharmaceuticals stock | $1.02

Corbus Pharmaceuticals Holdings, Inc is a biotechnology business based in the US. Corbus Pharmaceuticals shares (CRBP) are listed on the NASDAQ and all prices are listed in US Dollars. Corbus Pharmaceuticals employs 141 staff and has a trailing 12-month revenue of around USD$5.9 million.

How to buy shares in Corbus Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Corbus Pharmaceuticals. Find the stock by name or ticker symbol: CRBP. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Corbus Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$1.02, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Corbus Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Corbus Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Corbus Pharmaceuticals share price

Use our graph to track the performance of CRBP stocks over time.

Corbus Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-12-26.

Latest market close	USD$1.02
52-week range	USD$0.91 - USD$9.78
50-day moving average	USD$1.3106
200-day moving average	USD$4.1646
Wall St. target price	USD$6.9
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.93

Buy Corbus Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Corbus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Corbus Pharmaceuticals Holdings, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Corbus Pharmaceuticals price performance over time

Historical closes compared with the close of $1.02 from 2020-10-19

1 week (2021-01-15)	-41.38%
1 month (2020-12-23)	-29.17%
3 months (2020-10-23)	0.99%
6 months (2020-07-23)	-85.00%

1 year (2020-01-22)	-85.85%
2 years (2019-01-22)	-86.80%
3 years (2018-01-22)	8.8
5 years (2016-01-22)	1.5

Corbus Pharmaceuticals financials

Revenue TTM	USD$5.9 million
Gross profit TTM	USD$-53,461,222
Return on assets TTM	-98.49%
Return on equity TTM	-439.09%
Profit margin	0%
Book value	$0.356
Market capitalisation	USD$116.8 million

TTM: trailing 12 months

Shorting Corbus Pharmaceuticals shares

There are currently 31.7 million Corbus Pharmaceuticals shares held short by investors – that's known as Corbus Pharmaceuticals's "short interest". This figure is 10.4% down from 35.3 million last month.

There are a few different ways that this level of interest in shorting Corbus Pharmaceuticals shares can be evaluated.

Corbus Pharmaceuticals's "short interest ratio" (SIR)

Corbus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Corbus Pharmaceuticals shares currently shorted divided by the average quantity of Corbus Pharmaceuticals shares traded daily (recently around 4.6 million). Corbus Pharmaceuticals's SIR currently stands at 6.84. In other words for every 100,000 Corbus Pharmaceuticals shares traded daily on the market, roughly 6840 shares are currently held short.

However Corbus Pharmaceuticals's short interest can also be evaluated against the total number of Corbus Pharmaceuticals shares, or, against the total number of tradable Corbus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Corbus Pharmaceuticals's short interest could be expressed as 0.38% of the outstanding shares (for every 100,000 Corbus Pharmaceuticals shares in existence, roughly 380 shares are currently held short) or 0.4619% of the tradable shares (for every 100,000 tradable Corbus Pharmaceuticals shares, roughly 462 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Corbus Pharmaceuticals.

Find out more about how you can short Corbus Pharmaceuticals stock.

Corbus Pharmaceuticals share dividends

We're not expecting Corbus Pharmaceuticals to pay a dividend over the next 12 months.

Corbus Pharmaceuticals share price volatility

Over the last 12 months, Corbus Pharmaceuticals's shares have ranged in value from as little as $0.91 up to $9.78. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corbus Pharmaceuticals's is 2.1417. This would suggest that Corbus Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Corbus Pharmaceuticals overview

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.

Frequently asked questions

• What percentage of Corbus Pharmaceuticals is owned by insiders or institutions?

  Currently 1.73% of Corbus Pharmaceuticals shares are held by insiders and 75.483% by institutions.

• How many people work for Corbus Pharmaceuticals?

  Latest data suggests 141 work at Corbus Pharmaceuticals.

• When does the fiscal year end for Corbus Pharmaceuticals?

  Corbus Pharmaceuticals's fiscal year ends in December.

• Where is Corbus Pharmaceuticals based?

  Corbus Pharmaceuticals's address is: 500 River Ridge Drive, Norwood, MA, United States, 02062

• What is Corbus Pharmaceuticals's ISIN number?

  Corbus Pharmaceuticals's international securities identification number is: US21833P1030

• What is Corbus Pharmaceuticals's CUSIP number?

  Corbus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 21833P103